CA2347067C - Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer - Google Patents
Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer Download PDFInfo
- Publication number
- CA2347067C CA2347067C CA2347067A CA2347067A CA2347067C CA 2347067 C CA2347067 C CA 2347067C CA 2347067 A CA2347067 A CA 2347067A CA 2347067 A CA2347067 A CA 2347067A CA 2347067 C CA2347067 C CA 2347067C
- Authority
- CA
- Canada
- Prior art keywords
- trt
- cells
- cell
- dcs
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010017842 Telomerase Proteins 0.000 title claims abstract description 23
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 title claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 title abstract description 32
- 238000011282 treatment Methods 0.000 title abstract description 4
- 201000011510 cancer Diseases 0.000 title description 20
- 229940029030 dendritic cell vaccine Drugs 0.000 title description 2
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 41
- 229920001184 polypeptide Polymers 0.000 claims abstract description 40
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 17
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 17
- 239000002157 polynucleotide Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 106
- 239000000427 antigen Substances 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 239000002243 precursor Substances 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract description 105
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract description 105
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 41
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 description 16
- 210000000612 antigen-presenting cell Anatomy 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000043129 MHC class I family Human genes 0.000 description 8
- 108091054437 MHC class I family Proteins 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000015215 Stem Cell Factor Human genes 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11200698P | 1998-03-31 | 1998-03-31 | |
| US60/112,006 | 1998-03-31 | ||
| PCT/US1999/006898 WO1999050392A1 (en) | 1998-03-31 | 1999-03-30 | Methods and compositions for eliciting an immune response to a telomerase antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2347067A1 CA2347067A1 (en) | 1999-10-07 |
| CA2347067C true CA2347067C (en) | 2013-09-17 |
Family
ID=22341634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2347067A Expired - Lifetime CA2347067C (en) | 1998-03-31 | 1999-03-30 | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6440735B1 (enExample) |
| EP (1) | EP1068296B1 (enExample) |
| JP (3) | JP2002509716A (enExample) |
| AU (1) | AU3456099A (enExample) |
| CA (1) | CA2347067C (enExample) |
| WO (1) | WO1999050392A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093809A (en) * | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6261836B1 (en) * | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US6808880B2 (en) * | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
| US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| CN102021153B (zh) | 1996-10-01 | 2016-05-25 | 杰龙公司 | 人类的端粒酶催化亚单位 |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US7413864B2 (en) * | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
| US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US20020142974A1 (en) * | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
| CA2344972A1 (en) * | 1998-10-29 | 2000-05-11 | Dana-Farber Cancer Institute, Inc. | Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert |
| EP1171612A2 (en) * | 1999-04-09 | 2002-01-16 | Biomira, Inc. | Telomerase-specific cancer vaccine |
| EP1257284A4 (en) * | 2000-02-15 | 2005-12-21 | Univ California | UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE |
| AU2001241533A1 (en) | 2000-02-15 | 2001-08-27 | The Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| GB0031430D0 (en) * | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
| US7695725B2 (en) * | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| KR101192652B1 (ko) * | 2003-02-06 | 2012-10-19 | 앤저 테라퓨틱스 인코퍼레이티드 | 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법 |
| US7833775B2 (en) * | 2003-02-06 | 2010-11-16 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| CN101068574B (zh) | 2004-07-20 | 2012-07-18 | 伊索格尼斯股份有限公司 | 与自身抗原有关的自身免疫和疾病的特异性抑制 |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| JPWO2006025526A1 (ja) * | 2004-09-03 | 2008-05-08 | 株式会社医学生物学研究所 | Ｃｔｌ誘導能を獲得した樹状細胞の製造方法 |
| EP1801230A4 (en) * | 2004-09-03 | 2008-03-05 | Medical & Biol Lab Co Ltd | METHOD FOR SELECTING LIGHT AS AN ANTIGEN PROTEINS PRESENTED ON DENTRIC CELLS |
| JP5855326B2 (ja) | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | 抗ｋｉｒ組み合わせ治療および方法 |
| IL316252A (en) | 2005-03-23 | 2024-12-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| RU2309753C1 (ru) * | 2006-05-05 | 2007-11-10 | ЗАО "РеМеТэкс" | Комбинированный клеточный трансплантат на основе лимфокинактивированных киллеров и дендритных клеток, способ его получения и способ лечения и профилактики онкологических, инфекционных заболеваний и иммунодефицитных состояний |
| EP3753576A1 (en) | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| WO2010096693A2 (en) * | 2009-02-19 | 2010-08-26 | Mayo Foundation For Medical Education And Research | Methods and materials for generating t cells |
| US8563307B2 (en) | 2009-02-24 | 2013-10-22 | James Wang | Treatment of immunosuppression-related disorders |
| ES2751092T3 (es) | 2010-02-16 | 2020-03-30 | Ultimovacs Asa | Polipéptidos |
| DK3904391T3 (en) | 2010-03-10 | 2024-10-14 | Genmab As | Monoclonal antibodies against c-met |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| PT2580243T (pt) | 2010-06-09 | 2020-01-22 | Genmab As | Anticorpos contra cd38 humana |
| HUE035599T2 (en) | 2010-06-15 | 2018-05-28 | Genmab As | Human antibody drug conjugates against tissue factor |
| US8679474B2 (en) * | 2010-08-04 | 2014-03-25 | StemBios Technologies, Inc. | Somatic stem cells |
| US20140170149A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
| EP4520771A3 (en) | 2011-04-20 | 2025-07-16 | Genmab A/S | Bispecifc antibodies against her2 |
| TWI571513B (zh) | 2011-09-28 | 2017-02-21 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
| EP2929013B1 (en) | 2012-12-06 | 2020-02-05 | Stembios Technologies, Inc. | Lgr5+ somatic stem cells |
| EP2746769A1 (en) | 2012-12-21 | 2014-06-25 | Stembios Technologies, Inc. | Method for evaluating effect of action on subject based on stem celldynamics |
| WO2016089610A1 (en) | 2014-12-06 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for cancer immunotherapy |
| US11020465B2 (en) | 2016-03-04 | 2021-06-01 | The Trustees Of Columbia University In The City Of New York | Development of dual whole cell-based vaccine against pancreatic cancer |
| US20190167722A1 (en) * | 2016-08-02 | 2019-06-06 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| WO2018064588A2 (en) * | 2016-09-30 | 2018-04-05 | Weiner, David | Tert immunogenic compositions and methods of treatment using the same |
| WO2018156434A1 (en) | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tim3-binding chimeric antigen receptors |
| JP7141725B2 (ja) | 2017-07-07 | 2022-09-26 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 変異ｃｄ２８共刺激ドメインを有するキメラ抗原受容体 |
| EP3737391A4 (en) | 2018-01-08 | 2022-03-23 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS |
| CN111867613A (zh) | 2018-01-09 | 2020-10-30 | H·李·莫菲特癌症中心和研究所公司 | 靶向表达clec12a的癌症的组合物和方法 |
| EP4069245A1 (en) | 2019-12-02 | 2022-10-12 | Celgene Corporation | Therapy for the treatment of cancer |
| CA3172894A1 (en) | 2020-02-27 | 2021-09-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tumor-infiltrating lymphocytes with enhanced tumor reactivity |
| CA3175491A1 (en) | 2020-05-05 | 2021-11-11 | David DILILLO | Car comprising cd28 zeta and cd3 zeta |
| WO2024206155A1 (en) | 2023-03-24 | 2024-10-03 | Cornell University | Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0147689B1 (en) | 1983-12-05 | 1990-09-19 | Asahi Kasei Kogyo Kabushiki Kaisha | A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process |
| US6004807A (en) | 1992-03-30 | 1999-12-21 | Schering Corporation | In vitro generation of human dendritic cells |
| AU687733B2 (en) | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| CA2133409C (en) | 1992-04-01 | 2011-05-24 | Ralph M. Steinman | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| IL105503A (en) | 1992-04-28 | 1999-05-09 | Astra Ab | Carbon peptide couplets capable of eliciting an immune response of T cells |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5648215A (en) | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5645986A (en) * | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1994002156A1 (en) * | 1992-07-16 | 1994-02-03 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate t cells |
| US6077519A (en) | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| EP0692973A1 (en) | 1993-03-15 | 1996-01-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Peptide coated dendritic cells as immunogens |
| DE69435010T2 (de) * | 1993-04-20 | 2008-04-30 | Hipler Partners Llp | Verfahren und stoffe für die behandlung von individuen, die infiziert sind mit intrazellulär infektiösen agentien |
| IT1264516B1 (it) | 1993-05-31 | 1996-09-24 | Biotop Sas Di Rita Cassarin | Cellule dendritiche immortalizzate |
| DE4412794A1 (de) | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens |
| DK0765386T3 (en) | 1994-06-14 | 2015-01-26 | Univ Leland Stanford Junior | Methods for T cell activation in vivo with antigen-incubated dendritic cells |
| US5972627A (en) | 1994-06-15 | 1999-10-26 | Systemix, Inc. | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby |
| JP3680219B2 (ja) | 1994-06-28 | 2005-08-10 | 独立行政法人理化学研究所 | 癌細胞障害性ｔリンパ球の誘導培養方法 |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5648219A (en) | 1995-06-07 | 1997-07-15 | Zymogenetics, Inc. | Immortalized dendritic cells |
| US6010905A (en) | 1995-01-27 | 2000-01-04 | The United States Of America As Represented By The Department Of Health & Human Services | Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells |
| US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
| US5871728A (en) | 1995-03-31 | 1999-02-16 | University Of Pittsburgh | Method of regulating dendritic cell maturation |
| US5656638A (en) * | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US6015554A (en) | 1995-06-07 | 2000-01-18 | Systemix, Inc. | Method of reconstituting human lymphoid and dendritic cells |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US5968506A (en) * | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
| AU7152296A (en) | 1995-08-16 | 1997-03-12 | Board Of Trustees Of The Leland Stanford Junior University | Adult oligodendrocyte precursor cell compositions and methods |
| US5858777A (en) | 1995-09-08 | 1999-01-12 | Geron Corporation | Methods and reagents for regulating telomere length and telomerase activity |
| AU1152397A (en) | 1995-12-20 | 1997-07-14 | Board Of Trustees Of The Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
| US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
| DE69734974D1 (de) | 1996-02-08 | 2006-02-02 | Us Gov Health & Human Serv | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| WO1997040182A1 (de) | 1996-04-19 | 1997-10-30 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US5747317A (en) | 1996-07-08 | 1998-05-05 | Tularik Inc. | Human telomerase RNA interacting protein gene |
| US5770422A (en) | 1996-07-08 | 1998-06-23 | The Regents Of The University Of California | Human telomerase |
| IL127912A0 (en) | 1996-07-10 | 1999-11-30 | Immunex Corp | Method of activating dendritic cells |
| US6017527A (en) | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| WO1998007838A1 (en) | 1996-08-21 | 1998-02-26 | Mitsubishi Chemical Corporation | Higher animal telomerase protein and gene encoding the same |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6261836B1 (en) * | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| CN102021153B (zh) * | 1996-10-01 | 2016-05-25 | 杰龙公司 | 人类的端粒酶催化亚单位 |
| CH689672A9 (de) | 1996-10-01 | 2000-02-29 | Geron Corp | Katalytische Untereinheit menschlicher Telomerase. |
| US5812477A (en) | 1996-10-03 | 1998-09-22 | Micron Technology, Inc. | Antifuse detection circuit |
| US6008004A (en) | 1996-10-04 | 1999-12-28 | Becton Dickinson & Company | Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues |
| JP2001503976A (ja) | 1996-10-10 | 2001-03-27 | デューク ユニヴァーシティ | 樹状細胞の成熟を補助する胸腺微環境の生産法 |
| US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
| US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| US7390891B1 (en) | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| AU5686898A (en) | 1996-11-26 | 1998-06-22 | Baylor College Of Medicine | Identification of inhibitors that prevent access of telomerase to chrom osomal terminus |
| WO1998037181A2 (en) | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| CA2286819A1 (en) | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| AUPO723097A0 (en) | 1997-06-06 | 1997-07-03 | Australian National University, The | A method for culturing cells |
| CA2294646A1 (en) | 1997-06-20 | 1998-12-30 | Bayer Aktiengesellschaft | Human catalytic telomerase sub-unit and its diagnostic and therapeutic use |
| WO1998059046A1 (en) | 1997-06-25 | 1998-12-30 | The Regents Of The University Of California | Rice beta-glucanase enzymes and genes |
| KR100581990B1 (ko) | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| WO1999025812A1 (en) | 1997-11-14 | 1999-05-27 | Hemosol Inc. | Method for the production and use of dendritic cells |
| JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
| WO1999051255A1 (en) | 1998-04-06 | 1999-10-14 | The Johns Hopkins University School Of Medicine | Telomerase-associated proteins |
| NZ508936A (en) | 1998-06-02 | 2005-01-28 | Dendreon Corp | Method for preparation and in vivo administration of antigen presenting cell composition |
| US6277613B1 (en) | 1998-06-10 | 2001-08-21 | The Rockefeller University | TRF1 binding protein, methods of use thereof |
| EP1085892A4 (en) | 1998-06-12 | 2002-07-17 | Sloan Kettering Inst Cancer | VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US6482405B1 (en) | 1998-09-15 | 2002-11-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| CA2344972A1 (en) | 1998-10-29 | 2000-05-11 | Dana-Farber Cancer Institute, Inc. | Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert |
| GB9824306D0 (en) | 1998-11-05 | 1998-12-30 | Isis Innovation | Method for producing dendritic dells |
| EP1171612A2 (en) * | 1999-04-09 | 2002-01-16 | Biomira, Inc. | Telomerase-specific cancer vaccine |
-
1999
- 1999-03-30 JP JP2000541280A patent/JP2002509716A/ja not_active Withdrawn
- 1999-03-30 CA CA2347067A patent/CA2347067C/en not_active Expired - Lifetime
- 1999-03-30 WO PCT/US1999/006898 patent/WO1999050392A1/en not_active Ceased
- 1999-03-30 EP EP99916193A patent/EP1068296B1/en not_active Expired - Lifetime
- 1999-03-30 AU AU34560/99A patent/AU3456099A/en not_active Abandoned
-
2000
- 2000-09-29 US US09/675,321 patent/US6440735B1/en not_active Expired - Lifetime
-
2005
- 2005-09-16 JP JP2005271209A patent/JP2006020648A/ja not_active Withdrawn
-
2006
- 2006-12-27 JP JP2006353532A patent/JP2007137889A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU3456099A (en) | 1999-10-18 |
| US6440735B1 (en) | 2002-08-27 |
| JP2006020648A (ja) | 2006-01-26 |
| EP1068296B1 (en) | 2011-08-10 |
| WO1999050392A1 (en) | 1999-10-07 |
| CA2347067A1 (en) | 1999-10-07 |
| EP1068296A1 (en) | 2001-01-17 |
| JP2007137889A (ja) | 2007-06-07 |
| JP2002509716A (ja) | 2002-04-02 |
| EP1068296A4 (en) | 2003-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2347067C (en) | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer | |
| Butterfield et al. | Adenovirus MART-1–engineered autologous dendritic cell vaccine for metastatic melanoma | |
| KR101243577B1 (ko) | 성숙 수지상 세포 조성물 및 그의 배양 방법 | |
| CA2700436C (en) | Cancer vaccines and vaccination methods | |
| JP6230208B2 (ja) | 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激 | |
| EP1326961B1 (en) | Compositions and methods for inducing specific cytolytic t cell responses | |
| Schnell et al. | Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells | |
| WO1994002156A1 (en) | Methods for using dendritic cells to activate t cells | |
| JP2011504101A5 (enExample) | ||
| JP2008521406A (ja) | 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法 | |
| EP2305796A1 (en) | Process for producing cytotoxic lymphocytes | |
| US20180078626A1 (en) | Compositions and methods of treating renal cell cancer | |
| US7824849B2 (en) | Cellular telomerase vaccine and its use for treating cancer | |
| JP5054875B2 (ja) | 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球 | |
| AU758265B2 (en) | Induction of immunity against tumor self-antigens | |
| JP2003521936A5 (enExample) | ||
| JP2002506633A (ja) | Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法 | |
| AU755156B2 (en) | Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby | |
| Voss et al. | Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine | |
| CA2362295A1 (en) | Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules | |
| AU2007231612B2 (en) | Immune effector cell hybrids | |
| Patterson | Graft-versus-myeloid leukemia responses in murine bone marrow transplantations | |
| AU2001238236A1 (en) | Cytotoxic T Lymphocytes Activated by Dendritic Cell Hybrids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20190401 |